Potential Savings Associated with Drug Substitution in Medicare Part D: The Translating Research into Action for Diabetes (TRIAD) Study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Drug substitution is a promising approach to reducing medication costs.
To calculate the potential savings in a Medicare Part D plan from generic or therapeutic substitution for commonly prescribed drugs.
Cross-sectional, simulation analysis.
Low-income subsidy (LIS) beneficiaries (n = 145,056) and non low-income subsidy (non-LIS) beneficiaries (n = 1,040,030) enrolled in a large, national Part D health insurer in 2007 and eligible for a possible substitution.
Using administrative data from 2007, we identified claims filled for brand-name drugs for which a direct generic substitute was available. We also identified the 50 highest cost drugs separately for LIS and non-LIS beneficiaries, and reached consensus on which drugs had possible therapeutic substitutes (27 for LIS, 30 for non-LIS). For each possible substitution, we used average daily costs of the original and substitute drugs to calculate the potential out-of-pocket savings, health plan savings, and when applicable, savings for the government/LIS subsidy.
Overall, 39 % of LIS beneficiaries and 51 % of non-LIS beneficiaries were eligible for a generic and/or therapeutic substitution. Generic substitutions resulted in an average annual savings of $160 in the case of LIS beneficiaries and $127 in the case of non-LIS beneficiaries. Therapeutic substitutions resulted in an average annual savings of $452 in the case of LIS beneficiaries and $389 in the case of non-LIS beneficiaries.
Our findings indicate that drug substitution, particularly therapeutic substitution, could result in significant cost savings. There is a need for additional studies evaluating the acceptability of therapeutic substitution interventions within Medicare Part D.
- The Henry J. Kaiser Family Foundation. Medicare Chartbook, Fourth Edition, 2010. Menlo Park, CA: Kaiser Family Foundation. Available at: www.kff.org/medicare/upload/8103.pdf. Accessed December 4, 2012.
- The Henry J. Kaiser Family Foundation. Retail prescription drugs filled at pharmacies (Annual per capita by age), 2009. Menlo Park, CA: Kaiser Family Foundation. Available at: http://www.statehealthfacts.org/comparetable.jsp?ind=268&cat=5. Accessed December 4, 2012.
- Madden, JM, Graves, AJ, Ross-Degnan, D, Briesacher, BA, Soumerai, SB (2009) Cost-related medication nonadherence after implementation of Medicare Part D, 2006–2007. JAMA 302: pp. 1755-6 CrossRef
- The Henry J. Kaiser Family Foundation. Explaining health care reform: key changes to the Medicare Part D drug benefit coverage gap, 2010. Menlo Park, CA: Kaiser Family Foundation. Available at: http://www.kff.org/healthreform/upload/8059.pdf. Accessed December 4, 2012.
- Aitken, M, Berndt, ER, Cutler, DM (2009) Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood) 28: pp. w151-60 CrossRef
- Gilman, BH, Kautter, J (2008) Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries. Health Serv Res 43: pp. 478-95 CrossRef
- Hartman, M, Martin, A, Nuccio, O, Catlin, A (2010) Health spending growth at a historic low in 2008. Health Aff (Millwood) 29: pp. 147-55 CrossRef
- Zhang, JX, Yin, W, Sun, SX, Alexander, GC (2008) The impact of the Medicare Part D prescription benefit on generic drug use. J Gen Intern Med 23: pp. 1673-8 CrossRef
- Levinson DR. Generic drug utilization in the Medicare Part D program. Washington, DC: Department of Health and Human Services, OEI-05-07-00130, 2007. Available at: https://oig.hhs.gov/oei/reports/oei-05-07-00130.pdf. Accessed December 4, 2012.
- Fischer, MA, Avorn, J (2004) Economic implications of evidence-based prescribing for hypertension: can better care cost less?. JAMA 291: pp. 1850-6 CrossRef
- Schneeweiss, S, Maclure, M, Dormuth, CR, Glynn, RJ, Canning, C, Avorn, J (2006) A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther 79: pp. 379-88 CrossRef
- Moon, JC, Bogle, RG (2006) Switching statins. BMJ 332: pp. 1344-5 CrossRef
- Gumbs, PD, Verschuren, WM, Souverein, PC (2007) Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol 64: pp. 680-5 CrossRef
- ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health Syst Pharm 65: pp. 1368-84 CrossRef
- ACCP position statement: guidelines for therapeutic interchange. Pharmacotherapy 25: pp. 1666-80 CrossRef
- Cheetham, TC, Chan, J, Benson, V, Richmond, C, Levin, E, Campen, D (2005) Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug. Am J Manag Care 11: pp. 546-52
- Billups, SJ, Plushner, SL, Olson, KL, Koehler, TJ, Kerzee, J (2005) Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. J Manag Care Pharm 11: pp. 681-6
- Sy, FZ, Choe, HM, Kennedy, DM (2009) Moving from A to Z: successful implementation of a statin switch program by a large physician group. Am J Manag Care 15: pp. 233-40
- Freeman, MK, White, W, Iranikhah, M (2012) Tablet splitting: a review of weight and content uniformity. Consult Pharm 27: pp. 341-52 CrossRef
- Freeman, MK, White, W, Iranikhah, M (2012) Tablet splitting: a review of the clinical and economic outcomes and patient acceptance. Second of a 2-part series. Consult Pharm 27: pp. 421-30 CrossRef
- Gee, M, Hasson, NK, Hahn, T, Ryono, R (2002) Effects of a tablet-splitting program in patients taking HMG-CoA reductase inhibitors: Analysis of clinical effects, patient satisfaction, compliance, and cost avoidance. J Manag Care Pharm 8: pp. 453-8
- Weissman, EM, Dellenbaugh, C (2007) Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia. Psychiatr Serv 58: pp. 201-6 CrossRef
- Tseng, CW, Buenconsejo-Lum, L, Manlucu, L, Hixon, A (2006) Physicians’ willingness and barriers to considering cost when prescribing. Hawaii Med J 65: pp. 320-1
- Potential Savings Associated with Drug Substitution in Medicare Part D: The Translating Research into Action for Diabetes (TRIAD) Study
Journal of General Internal Medicine
Volume 29, Issue 1 , pp 230-236
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- health care policy
- Industry Sectors
- Author Affiliations
- 1. David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- 4. Department of Health Policy and Management, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA
- 2. John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
- 3. Pacific Health Research and Education Institute, Honolulu, HI, USA